Telomir Pharmaceuticals Inc. has announced favorable results from a series of Good Laboratory Practice $(GLP)$ toxicology and safety pharmacology studies for its lead therapeutic candidate, Telomir-1 (Zn-Telomir). The studies, conducted in both in vitro systems and in vivo rat and dog models, found that Telomir-1 was generally well tolerated, with no treatment-related or dose-limiting toxicities observed. The company reported no adverse effects on cardiovascular, respiratory, or phototoxicity parameters, and any observed findings were limited, reversible, and considered non-adverse. Telomir Pharmaceuticals is preparing for the submission of an Investigational New Drug $(IND)$ application in the first quarter of 2026 and anticipates beginning first-in-human clinical studies in the first half of 2026. The company is also planning to submit scientific manuscripts for publication and to present data at multiple oncology-focused scientific conferences in 2026.